Schr ö dinger's IPO on NASDAQ raised $200 million

Recently, Schr ö dinger announced its listing on Nasdaq, raising more than $200 million It is worth mentioning that this is about 33% higher than the expected $150 million fundraising! This also reflects the capital market's optimism for the company Schr ö dinger, headquartered in New York, is focused on accelerating drug development and material design with its leading AI computing platform Specifically, based on the insights of physics and chemistry, the platform can accurately predict the model, so as to find higher quality molecules at a lower cost and faster On its website, Schr ö dinger revealed data that, using its computing platform, it can evaluate billions of compound molecules every week Using conventional methods, the average pharmaceutical company can synthesize about 1000 candidate compounds in the drug discovery project every year Based on this powerful computing platform, many global multinational pharmaceutical companies have cooperated with Schr ö dinger company on new drug discovery projects, in order to shorten the process of new drug discovery Schr ö dinger can also iterate over and over before synthesis and testing to comprehensively evaluate and optimize the selection of compounds The most potential molecules in each round will be further optimized in the subsequent analysis Schr ö dinger also believes that compared with traditional methods, its technology is expected to bring higher success rate.